GSK shares plunge 8% on profit warning

A shock profit warning from GlaxoSmithKline sent its shares plummeting yesterday after the drug giant said "the shadow of Avandia would continue to make life difficult" in 2008.

Sales of the blockbuster diabetes drug Avandia fell by almost a third in the US last year following the publication of a report that linked it to an increased risk of heart attack. In the fourth quarter, sales were down 55 per cent to £130m.

GSK yesterday warned that earnings would fall this year due to weaker Avandia sales and fierce competition from generic drugs.

Shares in the company plunged 7.6 per cent, down 89p to 1,078p, the lowest level since 2004. The price had fallen as much as 9.5 per cent earlier in the day, the biggest daily decline for the group since it was formed in 2000.

Presenting his last set of results before he retires in May, GSK's chief executive, Jean-Pierre Garnier, said earnings per share would fall "by a mid-single-digit percentage" at constant exchange rates.

"The shadow of Avandia will continue over us in 2008 and make life a little bit more difficult for us," he warned. "But underneath all this, you have a very strong business. In fact, without the Avandia incident, the company would have grown 19 percent in 2007."

Analysts said the outlook was disappointing. Ben Yeoh, at Dresdner Kleinwort, said: "Consensus expectations were for low- to mid-single-digit earnings growth in 2008, and they are talking about a decline."

GSK has vigorously disputed the findings of the academic article on Avandia, which appeared in The New England Journal of Medicine last May. The drug company said the benefits of Avandia far outweighed any risks, but any turnaround in the product's fortunes are expected to take some time.

To add to the problems, delays in the portfolio of new drugs at GSK has dented investor confidence. The cervical cancer vaccine Cervarix, considered by some analysts to be the most important new product for Glaxo this decade, suffered a setback after the US Food and Drug Administration delayed approval of the treatment in December, pending more information.

Mr Garnier said the company expected to update the agency on Cervarix by the third quarter of 2008, which means the drug is unlikely to go on sale in the US before 2009.

Sales of the company's best seller, the asthma drug Advair, rose to £3.5bn from £3.3bn in 2006, but analysts are concerned that growth is slowing.

The company also flagged up heavier generic-drug competition to products such as Wellbutrin and Coreg, which treat depression and hypertension, respectively.

The impact of generic rivals added to a 3 per cent fall in US pharmaceutical sales to £9.3bn, while sterling's strength against the dollar left the group's overall revenues down 2 per cent to £22.7bn. Pre-tax profits came in ahead of forecasts at £7.8bn.

The group has embarked on a cost-cutting programme aimed at saving £700m a year by 2010. GSK said the savings would partly offset the impact of generic competition and the Avandia sales drop this year.

Despite the concerns, Mr Garnier said the company remained confident about the future. "Our fast-growing vaccines business, the resurgence of our consumer healthcare division and the strong performance of many key pharmaceutical products are all providing contributions to growth," he said.

GSK's incoming chief executive, Andrew Witty, said he had no intention of selling the consumer healthcare division, which owns brands such as the painkiller Panadol, Aquafresh toothpaste and drinks such as Lucozade, Horlicks and Ribena. The division saw sales increase by 14 per cent to nearly £3.5bn last year.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Marketing Services Manager - (communications, testing, DM)

£32000 - £35000 per annum + benefits: Ashdown Group: Marketing Services Manage...

Guru Careers: Finance Account Manager

£Neg. (DOE) + Excellent Benefits: Guru Careers: A Finance Account Manager with...

Ashdown Group: Java Developer - Hertfordshire - £47,000 + bonus + benefits

£40000 - £470000 per annum + bonus: Ashdown Group: Java Developer / J2EE Devel...

Ashdown Group: Direct Marketing Manager - B2C, Financial Services - Slough

£45000 - £55000 per annum + Benefits: Ashdown Group: An exciting opportunity h...

Day In a Page

Could cannabis oil reverse the effects of cancer?

Could cannabis oil reverse effects of cancer?

As a film following six patients receiving the controversial treatment is released, Kate Hilpern uncovers a very slippery issue
The Interview movie review: You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here

The Interview movie review

You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here
Rosetta space mission voted most important scientific breakthrough of 2014

A memorable year for science – if not for mice

The most important scientific breakthroughs of 2014
Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas
La Famille Bélier is being touted as this year's Amelie - so why are many in the deaf community outraged by it?

Deaf community outraged by La Famille Bélier

The new film tells the story of a deaf-mute farming family and is being touted as this year's Amelie
10 best high-end laptops

10 best high-end laptops

From lightweight and zippy devices to gaming beasts, we test the latest in top-spec portable computers
Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

The batsman has grown disillusioned after England’s Ashes debacle and allegations linking him to the Pietersen affair
Susie Wolff: A driving force in battle for equality behind the wheel

Susie Wolff: A driving force in battle for equality behind the wheel

The Williams driver has had plenty of doubters, but hopes she will be judged by her ability in the cockpit
Adam Gemili interview: 'No abs Adam' plans to muscle in on Usain Bolt's turf

'No abs Adam' plans to muscle in on Usain Bolt's turf

After a year touched by tragedy, Adam Gemili wants to become the sixth Briton to run a sub-10sec 100m
Calls for a military mental health 'quality mark'

Homeless Veterans campaign

Expert calls for military mental health 'quality mark'
Racton Man: Analysis shows famous skeleton was a 6ft Bronze Age superman

Meet Racton Man

Analysis shows famous skeleton was a 6ft Bronze Age superman
Garden Bridge: St Paul’s adds to £175m project’s troubled waters

Garden Bridge

St Paul’s adds to £175m project’s troubled waters